PDCD1LG2 Antikörper (PE)

Produktnummer ABIN2663274

Produktdetails anti-PDCD1LG2 Antikörper (PE)

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser PDCD1LG2 Antikörper ist konjugiert mit PE

Applikation: ELISA (Detection)

Aufreinigung: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Klon: TY25

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu PDCD1LG2

Target: PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))

Andere Bezeichnung: CD273 (PDCD1LG2 Produkte)

Synonyme: PDL2 antikoerper, B7DC antikoerper, Btdc antikoerper, CD273 antikoerper, PD-L2 antikoerper, PDCD1L2 antikoerper, bA574F11.2 antikoerper, B7-DC antikoerper, F730015O22Rik antikoerper, programmed cell death 1 ligand 2 antikoerper, PDCD1LG2 antikoerper, Pdcd1lg2 antikoerper

Hintergrund: B7-DC is also called programmed death ligand 2 (PDL2). It has recently been clustered as CD273. This ligand is a 42 kD member of the immunoglobulin receptor superfamily expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. The TY25 antibody has been reported to be useful for blocking PD-1 mediated interactions.